2nd Multi-Stakeholder Symposium on Improving Patient Access to Rare Disease Therapies
22 — 23 February 2017. Hotel Le Plaza, Brussels, Belgium
This Symposium on improving patient access to rare disease therapies brought together patient advocates, payers, HTA bodies, academics, clinicians, policy makers, investors and industry representatives. It enabled participants to understand the interests and challenges of each stakeholder group, to discuss current and emerging initiatives and to continue to work together to improve patients’ access to rare disease therapies.
See documents referred to during the Symposium here
Presentations from the Symposium:
1 Setting the scene, Yann le Cam, EURORDIS
2 PrimeMover Slides: Introduction, Charles Barker, PrimeMover Associates
4 The Importance of multi-stakeholder collaboration, Lucia Monaco, Fondazione Telethon
5 Collaborating for success, Karen Facey, HTAi
6 Prime, Adaptive pathways, Hans-Georg Eichler, EMA
7 A collaborative conversation, Charles Barker, PrimeMover Associates: part 1
8 A collaborative conversation, Charles Barker, PrimeMover Associates: part 2
9 A collaborative conversation, Charles Barker, PrimeMover Associates: part 3
11 Innovative performance based outcome ageements, Karen Facey, HTAi
13 Continued., Adam Hutchings, Dolon Ltd.
14 Feedback from Breakout 3, Karen Facey & Adrian Towse
15 Proposals for coordination of HTA across Europe, Wim Goettsch, EUNetHTA
16 Continued., Alicia Granados, efpia
17 Strengthening of the EU cooperation on HTA, Karolina Hanslik, DG SANTE, European Commission